尽管大量研究报道了三级淋巴结构（TLS）与接受免疫检查点抑制剂（ICIs）治疗的癌症患者的临床结果之间的关联，但仍然缺乏更新、更全面的荟萃分析。本研究的主要目的是通过分析三级淋巴结构（TLS）与接受 ICI 治疗的癌症患者临床结果之间的关联，探讨免疫治疗相关患者的预后生物标志物，从而探讨其对接受 ICI 治疗的癌症患者的预后价值。 ICI。截至 2024 年 2 月，我们对 PubMed、Embase、Web of Science 和 Cochrane 图书馆数据库进行了全面检索，以确定评估三级淋巴结构与接受 ICI 治疗的癌症患者临床结果之间关联的相关研究。临床结果为总生存期（OS）、无进展生存期（PFS）和客观缓解率（ORR）。本次荟萃分析纳入了 13 项研究，其中 9 项评估了 TLS 的预后价值。结果显示，高水平的 TLS 预测 OS（汇总 HR = 0.35，95% CI：0.24-0.53，p < 0.001）和 PFS（汇总 HR = 0.47，95% CI：0.31-0.72，p < 0.001）显着延长），而接受 ICI 治疗的癌症患者的 ORR 较低（汇总 OR = 3.78，95% CI：2.26-6.33，p< 0.001）。我们的结果表明，高水平的 TLS 可以预测接受 ICI 治疗的癌症患者的良好预后，并且有潜力成为免疫治疗相关患者的预后生物标志物。版权所有 © 2024 Li、Guo、Gong、Wang、Wang、Sun、Jiang 和 Yang。

Although numerous studies have reported the association between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with immune checkpoint inhibitors (ICIs), there remains a lack of a newer and more comprehensive meta-analysis. The main objective of this study is to explore prognostic biomarkers in immunotherapy-related patients, through analyzing the associations between tertiary lymphoid structures (TLSs) and clinical outcomes in cancer patients treated with ICIs, so as to investigate their prognostic value in cancer patients treated with ICIs.A comprehensive search was conducted until February 2024 across PubMed, Embase, Web of Science, and the Cochrane Library databases to identify relevant studies evaluating the association between tertiary lymphoid structures and clinical outcomes in cancer patients treated with ICIs. The clinical outcomes were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).Thirteen studies were incorporated in this meta-analysis, among which nine evaluated the prognostic value of TLSs. The results showed the high levels of TLSs predicted a significantly prolonged OS (pooled HR = 0.35, 95% CI: 0.24-0.53, p < 0.001) and PFS (pooled HR = 0.47, 95% CI: 0.31-0.72, p < 0.001), while lower ORR (pooled OR = 3.78, 95% CI: 2.26-6.33, p < 0.001) in cancer patients treated with ICIs.Our results indicated that high levels of TLSs could predict a favorable prognosis for cancer patients treated with ICIs and have the potential to become a prognostic biomarker of immunotherapy-related patients.Copyright © 2024 Li, Guo, Gong, Wang, Wang, Sun, Jiang and Yang.